Patents by Inventor Ze'ev Ronai

Ze'ev Ronai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of RNF5 and Uses Thereof
    Publication number: 20100077491
    Abstract: Provided herein are compositions and methods relating to the involvement of RNF5 in muscle wasting.
    Type: Application
    Filed: July 12, 2007
    Publication date: March 25, 2010
    Applicants: Burnham Institute for Medical Research, Mount Sinai School of Medicine
    Inventors: Ze'ev Ronai, Agnes DeLaunay, Kenneth Bromberg
  • INHIBITION OF TUMOR GROWTH AND METASTASIS BY ATF2-DERIVED PEPTIDES
    Publication number: 20090281025
    Abstract: The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies, such as radiation therapy, chemotherapy, or a combinations thereof. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor involved in promoting resistance and inhibition of apoptosis. The invention provides a compound that alters ATF2 activity, specifically amino-terminal fragments of ATF2 that retain the JNK binding domain. The invention provides methods for inhibiting tumor cell growth and for sensitizing tumor cells to apoptosis with such peptides.
    Type: Application
    Filed: October 17, 2005
    Publication date: November 12, 2009
    Applicant: Mount Sinai School Of Medicine of New York University
    Inventors: Anindita Bhoumik, Ze'ev Ronai
  • COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA
    Publication number: 20090054438
    Abstract: There are provided methods of inhibiting growth and metastasis of melanoma, methods of sensitizing melanoma cells to apoptosis, and methods of treating a subject having melanoma using acetyl isogambogic acid, celastrol, or a derivative thereof. There are further provided derivatives of celastrol and compositions comprising acetyl isogambogic acid, celastrol, or a derivative thereof.
    Type: Application
    Filed: August 15, 2008
    Publication date: February 26, 2009
    Applicant: Burnham Institute for Medical Research
    Inventors: Ze'ev A. Ronai, Anindita Bhoumik, Nicholas D.P. Cosford, Russell Dahl
  • INHIBITION OF ATF2 ACTIVITY TO TREAT CANCER
    Publication number: 20080139475
    Abstract: The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor which, in combination with other factors, renders the cells resistant and inhibits apopotosis of the cells. The invention provides an inhibitory ATF2 N-terminal fragment, specifically a fragment corresponding to amino acid residues 50-100 of ATF2 (termed peptide II). The invention provides methods for inhibiting tumor cell growth with such peptides.
    Type: Application
    Filed: November 26, 2007
    Publication date: June 12, 2008
    Applicant: Mount Sinai School of Medicine of New York University
    Inventor: Ze'ev Ronai
  • Inhibition of ATF2 activity to treat cancer
    Patent number: 7314855
    Abstract: The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor which, in combination with other factors, renders the cells resistant and inhibits apopotosis of the cells. The invention provides an inhibitory ATF2 N-terminal fragment, specifically a fragment corresponding to amino acid residues 50-100 of ATF2 (termed peptide II). The invention provides methods for inhibiting tumor cell growth with such peptides.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: January 1, 2008
    Assignee: Mount Sinai School of Medicine of New York University
    Inventor: Ze'ev Ronai